Who Supplies Enalapril to India from GERMANY

To import finished pharmaceutical formulations containing Enalapril into India, the foreign manufacturer must obtain an import license from the Directorate General of Foreign Trade (DGFT) and register the product with the Central Drugs Standard Control Organization (CDSCO). The registration process involves submitting Form 40, along with supporting documents such as the Certificate of Pharmaceutical Products (CoPP), Good Manufacturing Practice (GMP) certificate, and stability data. The registration is valid for three years. The import license is typically valid for one year and can be renewed. The timeline for obtaining these approvals can range from six months to a year, depending on the completeness of the application and regulatory processing times.

Imported Enalapril formulations must undergo quality testing at CDSCO-approved laboratories in India. Each batch requires a Certificate of Analysis (CoA) confirming compliance with Indian Pharmacopoeia standards. Stability data, particularly for ICH Zone IV conditions, must be provided to demonstrate the product's shelf-life under Indian climatic conditions. Port inspections by customs drug inspectors are conducted to verify the authenticity and quality of the imported products. If a batch fails quality testing, it may be rejected, leading to potential delays and additional costs for the importer.

Between 2024 and 2026, the CDSCO has implemented stricter regulations for the import of pharmaceutical formulations, including Enalapril. The introduction of the Production Linked Incentive (PLI) scheme has encouraged domestic manufacturing, potentially affecting the volume of finished formulation imports. Bilateral agreements between India and Germany have facilitated smoother trade relations, but importers must stay updated on any policy changes that may impact import procedures and duties.

India imports finished Enalapril formulations primarily due to the demand for patented or branded products, specific dosage forms not manufactured domestically, and the need for consistent quality. The domestic capacity to produce all required Enalapril formulations is limited, leading to a dependency on imports. The market size for Enalapril formulations in India is substantial, with a growing patient population requiring antihypertensive treatments.

The Basic Customs Duty (BCD) for Enalapril formulations under HS Code 30049071 is 10%. Additionally, a Social Welfare Surcharge (SWS) of 10% of the BCD is applicable. The Integrated Goods and Services Tax (IGST) is levied at 12%. There are no anti-dumping duties or exemptions applicable for Germany-origin products. The total landed duty percentage is approximately 32.2%.

India sources Enalapril formulations from Germany due to the country's strong reputation for high-quality pharmaceutical manufacturing, adherence to international GMP standards, and the availability of specialized dosage forms. Germany's share in India's Enalapril import market is significant, with other suppliers like China, the US, and domestic manufacturers also contributing to the market. Germany's competitive advantage lies in its consistent product quality and compliance with international regulatory standards.

India imports Enalapril formulations from Germany due to the availability of patented formulations, specialized dosage forms, and technology-licensed products that are not manufactured domestically. Germany's adherence to international quality standards and regulatory compliance makes it a preferred source for these formulations.

Compared to other sources like China, the EU, and the US, Germany offers a competitive advantage in terms of product quality, regulatory compliance, and reliability. While other countries may offer lower prices, Germany's consistent quality and adherence to international standards provide a unique advantage for Indian importers.

Potential risks include single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. Past shortages have been minimal, but importers should maintain contingency plans to mitigate these risks.

1. 1Dual-Sourcing: Engage multiple suppliers to reduce dependency on a single source.
2. 2Inventory Planning: Maintain adequate stock levels to buffer against supply chain disruptions.
3. 3Payment Terms: Negotiate favorable terms such as Letters of Credit (LC), Documents Against Acceptance (DA), or Documents Against Payment (DP).
4. 4Minimum Order Quantities (MOQs): Align procurement volumes with supplier MOQs to optimize costs.
5. 5Supplier Qualification: Conduct thorough due diligence to ensure supplier reliability and compliance with regulatory standards.

1. 1DGFT Import License: Obtain an import license from the Directorate General of Foreign Trade.
2. 2CDSCO Registration: Register the product with the Central Drugs Standard Control Organization.
3. 3Form 40 Application: Submit Form 40 along with required documents.
4. 4NOC: Obtain a No Objection Certificate if required.
5. 5Customs Broker: Engage a licensed customs house agent for clearance.
6. 6Advance Ruling: Seek an advance ruling for HS Code 30049071 if necessary.

1. 1Certificate of Analysis (CoA): Confirming product quality.
2. 2Certificate of Pharmaceutical Products (CoPP): Issued by the regulatory authority of Germany.
3. 3GMP Certificate: Demonstrating compliance with Good Manufacturing Practices.
4. 4Drug Master File (DMF): Providing detailed information about the drug substance.
5. 5Stability Data: For ICH Zone IVa/IVb conditions.
6. 6Free Sale Certificate: Indicating the product is freely sold in the country of origin.
7. 7Manufacturer Authorization